https://www.selleckchem.com/pr....oducts/ITF2357(Givin
In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist's intervention group (p = 0.001). CONCLUSIONS Clinical pharmacist's intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients.PURPOSE Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the
Like
Comment
Share
